
    
      This is a Phase 3, multicentre, open label, randomised controlled study in subjects diagnosed
      with low risk prostate cancer on TransRectal Ultrasound (TRUS) guided biopsy.

      Subjects will be randomised to either Active Surveillance or TOOKAD® Soluble VTP. Subjects
      will remain in the study for approximately 24 months following randomisation. A total of 400
      subjects will be entered into the study; 200 will receive Active Surveillance and 200 will
      receive TOOKAD® Soluble-VTP.
    
  